# Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants

> **NCT03978143** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 25 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Treatment A
- **DRUG:** Treatment B
- **DRUG:** Treatment C
- **DRUG:** Treatment D
- **DRUG:** Treatment E
- **DRUG:** Treatment F
- **DRUG:** Treatment G
- **DRUG:** Treatment H

## Key facts

- **NCT ID:** NCT03978143
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-12
- **Primary completion:** 2019-10-17
- **Final completion:** 2019-10-17
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03978143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03978143, "Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03978143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*